JNJ 28871063 hydrochloride
Cat. No. 3352
Chemical Name: 5E-4-Amino-6-(4-benzyloxy-3-chlorophenylamino)pyrimidine-5-carboxaldehyde N-(2-morpholin-4-ylethyl) oxime hydrochloride
Biological ActivityPotent and selective ErbB receptor family inhibitor (IC50 values are 21, 22 and 38 nM for ErbB4, EGFR and ErbB2 respectively). Displays potent growth inhibition of human cancer cell lines overexpressing ErbB2 in vitro (IC50 = 60 - 168 nM) and inhibits growth of human tumor xenografts in vivo. Brain penetrant and orally active.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Contessa and Hamstra (2008) Revoking the privilege: targeting HER2 in the central nervous system. Mol.Pharmacol. 73 271. PMID: 17981994.
Emanuel et al (2008) Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol.Pharmacol. 73 338. PMID: 17975007.
Guessous et al (2008) Signaling pathways in medulloblastoma. J.Cell.Phys. 217 577.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: JNJ 28871063 hydrochloride, supplier, Potent, ErbB, receptor, family, inhibitors, Epidermal, Growth, Factors, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, JNJ28871063, hydrochloride
Find multiple products by catalog number
New Products in this Area
TrkB receptor antagonistR 1530
Multi-RTK inhibitor; inhibits angiogenesisGNF 5837
Potent Trk inhibitor; inhibits TrkA, TrkB and TrkC
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.